Specifically, angiopoietin-2 (Ang-2), placental growth factor (PlGF), and ephrin A2 (EFNA2) have been observed at increased levels in GBM tissues resistant to bevacizumab [134]. The gene discussed is ANGPT2; the disease is glioblastoma.